Anette Hall1, Miguel Muñoz-Ruiz2, Jussi Mattila3, Juha Koikkalainen3, Magda Tsolaki4, Patrizia Mecocci5, Iwona Kloszewska6, Bruno Vellas7, Simon Lovestone8, Pieter Jelle Visser9, Jyrki Lötjonen3, Hilkka Soininen2. 1. Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland. 2. Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland Department of Neurology, Kuopio University Hospital, Kuopio, Finland. 3. VTT Technical Research Centre of Finland, Tampere, Finland. 4. Aristotle University of Thessaloniki, Memory and Dementia Centre, "G Papanicolaou" General Hospital, Thessaloniki, Greece. 5. Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy. 6. Medical University of Lodz, Lodz, Poland. 7. UMR INSERM, University of Toulouse, France. 8. National Institute for Health Research (NIHR), London, UK King's College London, Institute of Psychiatry, London, UK. 9. VU University Medical Center, Amsterdam, The Netherlands Maastricht University, Maastricht, The Netherlands.
Abstract
BACKGROUND: The Disease State Index (DSI) prediction model measures the similarity of patient data to diagnosed stable and progressive mild cognitive impairment (MCI) cases to identify patients who are progressing to Alzheimer's disease. OBJECTIVES: We evaluated how well the DSI generalizes across four different cohorts: DESCRIPA, ADNI, AddNeuroMed, and the Kuopio MCI study. METHODS: The accuracy of the DSI in predicting progression was examined for each cohort separately using 10 × 10-fold cross-validation and for inter-cohort validation using each cohort as a test set for the model built from the other independent cohorts using bootstrapping with 10 repetitions. Altogether 875 subjects were included in the analysis. The analyzed data included a comprehensive set of age and gender corrected magnetic resonance imaging (MRI) features from hippocampal volumetry, multi-template tensor-based morphometry, and voxel-based morphometry as well as Mini-Mental State Examination (MMSE), APOE genotype, and additional cohort specific data from neuropsychological tests and cerebrospinal fluid measurements (CSF). RESULTS: The DSI model was used to classify the patients into stable and progressive MCI cases. AddNeuroMed had the highest classification results of the cohorts, while ADNI and Kuopio MCI exhibited the lowest values. The MRI features alone achieved a good classification performance for all cohorts. For ADNI and DESCRIPA, adding MMSE, APOE genotype, CSF, and neuropsychological data improved the results. CONCLUSIONS: The results reveal that the prediction performance of the combined cohort is close to the average of the individual cohorts. It is feasible to use different cohorts as training sets for the DSI, if they are sufficiently similar.
BACKGROUND: The Disease State Index (DSI) prediction model measures the similarity of patient data to diagnosed stable and progressive mild cognitive impairment (MCI) cases to identify patients who are progressing to Alzheimer's disease. OBJECTIVES: We evaluated how well the DSI generalizes across four different cohorts: DESCRIPA, ADNI, AddNeuroMed, and the Kuopio MCI study. METHODS: The accuracy of the DSI in predicting progression was examined for each cohort separately using 10 × 10-fold cross-validation and for inter-cohort validation using each cohort as a test set for the model built from the other independent cohorts using bootstrapping with 10 repetitions. Altogether 875 subjects were included in the analysis. The analyzed data included a comprehensive set of age and gender corrected magnetic resonance imaging (MRI) features from hippocampal volumetry, multi-template tensor-based morphometry, and voxel-based morphometry as well as Mini-Mental State Examination (MMSE), APOE genotype, and additional cohort specific data from neuropsychological tests and cerebrospinal fluid measurements (CSF). RESULTS: The DSI model was used to classify the patients into stable and progressive MCI cases. AddNeuroMed had the highest classification results of the cohorts, while ADNI and Kuopio MCI exhibited the lowest values. The MRI features alone achieved a good classification performance for all cohorts. For ADNI and DESCRIPA, adding MMSE, APOE genotype, CSF, and neuropsychological data improved the results. CONCLUSIONS: The results reveal that the prediction performance of the combined cohort is close to the average of the individual cohorts. It is feasible to use different cohorts as training sets for the DSI, if they are sufficiently similar.
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Ingrid S van Maurik; Marissa D Zwan; Betty M Tijms; Femke H Bouwman; Charlotte E Teunissen; Philip Scheltens; Mike P Wattjes; Frederik Barkhof; Johannes Berkhof; Wiesje M van der Flier Journal: JAMA Neurol Date: 2017-12-01 Impact factor: 18.302
Authors: Antti Tolonen; Hanneke F M Rhodius-Meester; Marie Bruun; Juha Koikkalainen; Frederik Barkhof; Afina W Lemstra; Teddy Koene; Philip Scheltens; Charlotte E Teunissen; Tong Tong; Ricardo Guerrero; Andreas Schuh; Christian Ledig; Marta Baroni; Daniel Rueckert; Hilkka Soininen; Anne M Remes; Gunhild Waldemar; Steen G Hasselbalch; Patrizia Mecocci; Wiesje M van der Flier; Jyrki Lötjönen Journal: Front Aging Neurosci Date: 2018-04-25 Impact factor: 5.750
Authors: Marie Bruun; Hanneke F M Rhodius-Meester; Juha Koikkalainen; Marta Baroni; Le Gjerum; Afina W Lemstra; Frederik Barkhof; Anne M Remes; Timo Urhemaa; Antti Tolonen; Daniel Rueckert; Mark van Gils; Kristian S Frederiksen; Gunhild Waldemar; Philip Scheltens; Patrizia Mecocci; Hilkka Soininen; Jyrki Lötjönen; Steen G Hasselbalch; Wiesje M van der Flier Journal: Alzheimers Dement (Amst) Date: 2018-08-17
Authors: Anette Hall; Timo Pekkala; Tuomo Polvikoski; Mark van Gils; Miia Kivipelto; Jyrki Lötjönen; Jussi Mattila; Mia Kero; Liisa Myllykangas; Mira Mäkelä; Minna Oinas; Anders Paetau; Hilkka Soininen; Maarit Tanskanen; Alina Solomon Journal: Alzheimers Res Ther Date: 2019-01-22 Impact factor: 6.982
Authors: Marie Bruun; Kristian S Frederiksen; Hanneke F M Rhodius-Meester; Marta Baroni; Le Gjerum; Juha Koikkalainen; Timo Urhemaa; Antti Tolonen; Mark van Gils; Daniel Rueckert; Nadia Dyremose; Birgitte B Andersen; Afina W Lemstra; Merja Hallikainen; Sudhir Kurl; Sanna-Kaisa Herukka; Anne M Remes; Gunhild Waldemar; Hilkka Soininen; Patrizia Mecocci; Wiesje M van der Flier; Jyrki Lötjönen; Steen G Hasselbalch Journal: Alzheimers Res Ther Date: 2019-03-20 Impact factor: 6.982
Authors: Antti Cajanus; Anette Hall; Juha Koikkalainen; Eino Solje; Antti Tolonen; Timo Urhemaa; Yawu Liu; Ramona M Haanpää; Päivi Hartikainen; Seppo Helisalmi; Ville Korhonen; Daniel Rueckert; Steen Hasselbalch; Gunhild Waldemar; Patrizia Mecocci; Ritva Vanninen; Mark van Gils; Hilkka Soininen; Jyrki Lötjönen; Anne M Remes Journal: Dement Geriatr Cogn Dis Extra Date: 2018-02-23
Authors: Jaana Suvisaari; Outi Mantere; Jaakko Keinänen; Teemu Mäntylä; Eva Rikandi; Maija Lindgren; Tuula Kieseppä; Tuukka T Raij Journal: Front Psychiatry Date: 2018-11-13 Impact factor: 4.157